Most Popular
Research Trends
Can Childhood Metabolic Disorders Actually Lead to Heart Failure? Gene Therapy Research Provides Hope
Aug 18, 2023
Have you ever encountered patients who, despite growing normally during early childhood, gradually begin to exhibit symptoms such as facial abnormalities, growth retardation, delayed intellectual development, skeletal deformities, neurological abnormalities, and cardiac involvement? Read More >
Research Trends
Recommended Classic Mouse Models for Metabolic and Cardiovascular Diseases! Double Assurance with Validation Data and Efficacy Evaluation System
Aug 11, 2023
Cardiovascular diseases are now the leading cause of death worldwide, posing a significant threat to human health. In China alone, there are approximately 330 million people with cardiovascular disease and 450 million with metabolic disease. Read More >
Research Trends
What are the Best Transgenic Animal Models for Alzheimer's Disease Research?
Jun 20, 2023
When it comes to Alzheimer's disease (AD), people may think of various emotional scenes portrayed in movies and TV shows. However, the reality is much more cruel, as we can see from the trending topic“They Will Forget Love And They Will Forget You”. Read More >
Research Trends
Common Mouse Models for Preclinical Alzheimer's Disease Research
Jun 15, 2023
After being diagnosed with Alzheimer’s in his later years, the famous British fantasy author Terry Pratchett described the disease in his writings: “On the first day of my journalistic career I saw my first corpse… All I can say is that, compared with his horrific demise, Alzheimer's is a walk in the park. Except with Alzheimer's my park keeps changing. The trees get up and walk over there, the benches go missing and the paths seem to be unwinding into particularly vindictive serpents.”. Read More >
Research Trends
How to overcome the challenge of model selection in DMD gene therapy?
May 30, 2023
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder caused by mutations in the DMD gene, resulting in abnormal function of the dystrophin protein. Read More >
Research Trends
Advancements in CAR-T Cell Therapy: Maximizing Therapeutic Efficacy while Minimizing Toxicity
May 26, 2023
In the last chapter (click to review), we mentioned that chimeric antigen receptor (CAR)-T cell therapy has been extremely successful in treating relapsed/refractory B-cell malignancies expressing CD19, however, there are still many toxicities in clinical applications, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Read More >
Research Trends
What are the obstacles hindering the development of CAR-T therapy?
May 18, 2023
After years of development, chimeric antigen receptor (CAR) T cell therapy has become a revolutionary method for cancer treatment. Among them, CD19 targeting drugs have achieved unprecedented success in the treatment of B-cell malignancies and were approved by the US FDA in 2017. Read More >
Research Trends
Mastering CAR Structure and Design for Enhanced Anti-Tumor Response with CAR-T Cell Therapy
May 12, 2023
Chimeric antigen receptors (CARs) are engineered synthetic receptors that redirect lymphocytes, most commonly T-cells, to recognize and eliminate cells expressing specific target antigens. CAR binding to target antigens on the cell surface is independent of MHC receptors, resulting in vigorous T-cell activation and potent anti-tumor responses. Read More >
Research Trends
Frequently Asked Questions (FAQ) on Mouse Models for Ophthalmic Diseases
Apr 21, 2023
Due to the limited efficacy of traditional treatments, ophthalmic diseases have quickly become a breakthrough point for gene therapy, but many questions about mouse models for preclinical ophthalmology research remain. Read More >
Research Trends
Revolutionizing Neovascular Ophthalmology Research: Cyagen's Phenotypically Stable Humanized VEGF Mice
Apr 13, 2023
As a popular target for treating diseases like macular degeneration and tumors, vascular endothelial growth factor (VEGF) has already had several drugs approved for clinical use and has made significant progress. In February of this year, researchers completed the first Phase I clinical trial of a recombinant anti-VEGFA and VEGFC bispecific antibody fusion protein in a for age-related macular degeneration with neovascularization. Read More >